Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397471 | 0.81 | ALPI (0.32) | ALPI | |
| SCHEMBL4860458 | 0.64 | SLC5A2 (0.32) | ALPI | |
| SCHEMBL2047834 | 0.63 | SLC5A2 (0.32) | — | |
| SCHEMBL12589076 | 0.63 | NR1H2 (0.34) | — | |
| SCHEMBL12589077 | 0.62 | NR1H2 (0.38) | — | |
| SCHEMBL12589106 | 0.62 | SLC5A2 (0.31) | — | |
| SCHEMBL2047194 | 0.60 | SMN1; SMN2 (0.38) | — | |
| SCHEMBL2047098 | 0.57 | HSD17B2 (0.31) | — | |
| SCHEMBL12589052 | 0.57 | SLC5A2 (0.53) | — | |
| SCHEMBL31277159 | 0.57 | SRD5A2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20050143424-A1 | Prophylactic and therapeutic agent of diabetes mellitus | AJINOMOTO CO. INC (JP) | 2005-06-30 | — | — | US | disclosed |
| US-6908905-B2 | N-substituted pyrazole-O-glycoside derivatives and therapeutic agent for diabetes containing the same | AJINOMOTO CO., INC. (JP) | 2005-06-21 | — | — | US | disclosed |
| EP-1500403-A1 | PREVENTIVE/REMEDY FOR DIABETES | Ajinomoto Co., Inc. (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-20040110936-A1 | N-substituted pyrazole-O-glycoside derivatives and therapeutic agent for diabetes containing the same | AJINOMOTO CO., INC. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1389621-A1 | N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND REMEDIAL AGENT FOR DIABETES CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110936-A1 | N-substituted pyrazole-O-glycoside derivatives and therapeutic agent for diabetes containing the same | GPR119, SLC5A1, GLP1R | ALPI 908/4885 |
| US-20050143424-A1 | Prophylactic and therapeutic agent of diabetes mellitus | SLC5A2, SLC5A1, GPR119 | ALPI 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.